WTO fails to strike deal to waive COVID-19 IP

Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation (WTO) to conclude an agreement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

WTO declines to waive TRIPS provisions for COVID-19 drugs

25 January 2021 Representatives of South Africa and India have again tried and failed to persuade the World Trade Organization to waive IP rights related to COVID-19 treatments and vaccinations.

Big Pharma

South Africa, India urge WTO to waive IP for COVID-19 treatments

8 October 2020 South Africa and India have asked the World Trade Organization to cede some stipulations governing IP so that treatments to combat COVID-19 can become more widely available, particularly in low-income countries.

Big Pharma

WTO 'expected to announce' 17-year drug patent waiver for LDCs

4 November 2015 The World Trade Organization is expected to announce a 17-year extension to an agreement that exempts the world’s Least Developed Countries from a duty to grant patents covering pharmaceutical drugs, an activist group has claimed.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

WTO fails to strike deal to waive COVID-19 IP

More on this story

Editor's picks

Editor's picks

More features